170 related articles for article (PubMed ID: 35114569)
1. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
Yamatani K; Ai T; Saito K; Suzuki K; Hori A; Kinjo S; Ikeo K; Ruvolo V; Zhang W; Mak PY; Kaczkowski B; Harada H; Katayama K; Sugimoto Y; Myslinski J; Hato T; Miida T; Konopleva M; Hayashizaki Y; Carter BZ; Tabe Y; Andreeff M
Transl Oncol; 2022 Apr; 18():101354. PubMed ID: 35114569
[TBL] [Abstract][Full Text] [Related]
2. Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.
Hatırnaz Ng Ö; Eşkazan AE
Transl Oncol; 2022 May; 19():101394. PubMed ID: 35294914
[No Abstract] [Full Text] [Related]
3. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Patel AB; Pomicter AD; Yan D; Eiring AM; Antelope O; Schumacher JA; Kelley TW; Tantravahi SK; Kovacsovics TJ; Shami PJ; O'Hare T; Deininger MW
Leukemia; 2020 Nov; 34(11):2981-2991. PubMed ID: 32409689
[TBL] [Abstract][Full Text] [Related]
5. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
[TBL] [Abstract][Full Text] [Related]
6. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
7. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
8. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
Sheikhha MH; Awan A; Tobal K; Liu Yin JA
Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
[TBL] [Abstract][Full Text] [Related]
10. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Smith CC; Lin K; Stecula A; Sali A; Shah NP
Leukemia; 2015 Dec; 29(12):2390-2. PubMed ID: 26108694
[TBL] [Abstract][Full Text] [Related]
11. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
12. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
[TBL] [Abstract][Full Text] [Related]
14. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
[TBL] [Abstract][Full Text] [Related]
15. GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
Xiao X; Wang P; Zhang W; Wang J; Cai M; Jiang H; Wu Y; Shan H
Cancer Cell Int; 2023 Nov; 23(1):302. PubMed ID: 38037057
[TBL] [Abstract][Full Text] [Related]
16. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
17. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
19. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
20. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]